Paden King, Ph.D.

Paden King, Ph.D.
Postdoctoral Fellow (CRTA)
Molecular Imaging Branch

Team Member of:

Freddy E. Escorcia, M.D., Ph.D.

Dr. King is focused on the development of metal-based anticancer therapeutics. He will be applying his knowledge of inorganic chemistry in the lab to develop novel radiometal chelators and conjugates for cancer therapy.

Areas of Expertise

1) metals chemistry, 2) radiochemistry, 3) cancer molecular radiotherapy 

Contact Info

Paden King, Ph.D.
Center for Cancer Research
National Cancer Institute
Building 10, Room 1B55
Bethesda, MD 20892
Ph: 240-858-3062
paden.king@nih.gov

Selected Recent Publications

  1. Exploring the In Vivo and In Vitro Anticancer Activity of Rhenium Isonitrile Complexes.
    Marker SC, King AP, Granja S, Vaughn B, Woods JJ, Boros E, Wilson JJ.
    Inorg Chem. 59(14): 10285-10303, 2020. [ Journal Article ]
  2. Endoplasmic reticulum stress: an arising target for metal-based anticancer agents.
    King AP, Wilson JJ.
    Chem Soc Rev. Epub ahead of print, 2020. [ Journal Article ]
  3. Exploring Ovarian Cancer Cell Resistance to Rhenium Anticancer Complexes.
    Marker SC, King AP, Swanda RV, Vaughn B, Boros E, Qian SB, Wilson JJ.
    Angew Chem Int Ed Engl. Epub ahead of print, 2020. [ Journal Article ]
  4. Metal complexes as a promising source for new antibiotics.
    Frei A, Zuegg J, Elliott AG, Baker M, Braese S, Brown C, Chen F, G Dowson C, Dujardin G, Jung N, King AP, Mansour AM, Massi M, Moat J, Mohamed HA, Renfrew AK, Rutledge PJ, Sadler PJ, Todd MH, Willans CE, Wilson JJ, Cooper MA, Blaskovich MAT.
    Chem Sci. 11(10): 2627-2639, 2020. [ Journal Article ]
  5. In Vivo Anticancer Activity of a Rhenium(I) Tricarbonyl Complex.
    Konkankit CC, King AP, Knopf KM, Southard TL, Wilson JJ.
    ACS Med Chem Lett. 10(5): 822-827, 2019. [ Journal Article ]

Dr. Paden King was born and raised in the small town of Statenville, GA. Upon graduating high school, he proceeded to attend Mercer University, where he received Bachelor’s degrees in Chemistry and English Literature. His interest in medicinal chemistry led him to pursue his Ph.D. in bioinorganic chemistry at Cornell University where he worked in the laboratory of Professor Justin Wilson. While at Cornell, Dr. King focused on the development of metal-based anticancer therapeutics. Dr. King received his Ph.D. from Cornell in 2020 and has now joined Dr. Escorcia’s Lab so that he may apply his knowledge of inorganic chemistry to the development of novel radiometal chelators and conjugates for cancer therapy.